Fujifilm Irvine Scientific, a manufacturer of cell culture media for life science research, is acquiring Shenandoah Biotechnology, a manufacturer of recombinant proteins.
Shenandoah recently launched its CTG Grade line of cytokines and growth factors, manufactured according to cGMP guidelines in the company’s ISO 9001:2015 certified facility. The use of cGMP manufactured products is aimed to smooth the transition of biological therapies from preclinical to clinical phases.
“Fujifilm Irvine Scientific is committed to helping customers bring advanced therapies to market faster, and to use innovation to make therapies more accessible,” said Yutaka Yamaguchi, chair and CEO, Fujifilm Irvine Scientific. “Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs.”
“At Shenandoah Biotechnology, our vision is to provide a superior and affordable source of recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets. We are pleased to join Fujifilm Irvine Scientific given their experience with manufacturing ancillary materials for cell and gene therapy and commitment to providing high quality products and service to customers,” said Pamela De Lacy, President, Shenandoah Biotechnology. “We look forward to working with the team at Fujifilm Irvine Scientific and continuing to build on our success.”
